{
    "abstractText": "\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of The In Access article distributed under the terms of the Creative Commons Attribution-N which permits non-commercial re-use, distribution, and reproduction in any medi please contact journals.permissions@oup.com he figures make it clear that the data was for the NP213 pepide, the authors acknowledge they should have been clearer n the separation of the two nomenclatures within the text of he original manuscript. The authors would like to clarify that NP213 is the antifunal cyclo-7R compound and Novexatin\u00ae is the formulation rademark and should be read as such throughout this paper.",
    "authors": [],
    "id": "SP:b959a64c5ddedaa71d68cb260b8947e28d3c0a37",
    "references": [],
    "sections": [
        {
            "text": "t t i t\ng t\nt\nD ow nloaded from https://academ ic.o This is a correction to: Derry K Mercer and others, NP213 (Novexatin\u00ae): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile, Medical Mycology, Volume 58, Issue 8, Novermber 2020, Pages 1064\u2013 1072, https://doi.org/10.1093/mmy/myaa015. The original publication of the manuscript lacked clarification between the compound nomenclature (NP213) and trademark of the formulation (Novexatin\u00ae) in which the authors had intended to include the antifungal peptide. Although\n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of The In Access article distributed under the terms of the Creative Commons Attribution-N which permits non-commercial re-use, distribution, and reproduction in any medi please contact journals.permissions@oup.com\nhe figures make it clear that the data was for the NP213 pepide, the authors acknowledge they should have been clearer n the separation of the two nomenclatures within the text of he original manuscript.\nThe authors would like to clarify that NP213 is the antifunal cyclo-7R compound and Novexatin\u00ae is the formulation rademark and should be read as such throughout this paper.\nThis clarification has been made only in this correction noice to preserve the version of record.\nternational Society for Human and Animal Mycology. This is an Open onCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), um, provided the original work is properly cited. For commercial re-use,\nup.com /m m y/article/61/8/m yad088/7249019 by Indian Institute of Technology Patna user on 13 January 2024"
        }
    ],
    "title": "Correction to: NP213 (Novexatin\u00ae): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile",
    "year": 2023
}